Last updated: August 2, 2026
Akorn, Inc. was a U.S.-focused generic and specialty pharmaceutical company with commercial exposure concentrated in ophthalmic products, injectable drugs, and hospital-use medicines. Its competitive position deteriorated after manufacturing-quality findings, the collapse of Fresenius’ proposed acquisition, prolonged litigation, declining revenue, and a second Chapter 11 filing in 2023. Akorn subsequently pursued liquidation rather than a conventional growth strategy. Its former products and manufacturing assets remain relevant to generic competitors, contract manufacturers, and buyers evaluating abbreviated new drug application, or ANDA, opportunities.
What was Akorn’s market position in generic pharmaceuticals?
Akorn held a niche position in the U.S. generic drug market rather than competing at the scale of Viatris, Teva Pharmaceutical Industries, Sandoz, or Amneal Pharmaceuticals.
Its historical differentiation came from:
- Ophthalmic solutions, suspensions, gels, and ointments
- Sterile injectable products
- Hospital and institutional products
- Selected specialty and limited-competition generics
- Manufacturing facilities in the United States
- A portfolio developed through internal programs and acquisitions
Akorn reported net revenue of approximately $783 million in 2018, compared with approximately $630 million in 2017, before the company entered a prolonged period of regulatory and operational disruption.[1] The company’s principal commercial opportunity was in products where manufacturing complexity, sterile processing, ophthalmic delivery, or limited competition created higher barriers than standard oral tablets.
Akorn was not a biotechnology company in the conventional sense. It did not have an innovative biologics platform or a late-stage novel-molecule pipeline. Its value was tied to generic drug approvals, specialized dosage forms, manufacturing infrastructure, and commercial rights.
What products and therapeutic areas did Akorn commercialize?
Akorn’s portfolio included prescription ophthalmic products, injectable medicines, and other specialty generic drugs. Product availability changed over time because of manufacturing suspensions, recalls, product discontinuations, and the company’s financial collapse.
Ophthalmic products
Akorn’s historical ophthalmic portfolio included products such as:
- Akten, a lidocaine hydrochloride ophthalmic gel used as a topical ocular anesthetic
- Bromfenac ophthalmic products
- Cyclopentolate hydrochloride ophthalmic solution
- Flurbiprofen sodium ophthalmic solution
- Moxifloxacin ophthalmic solution
- Prednisolone acetate ophthalmic suspension
- Timolol maleate ophthalmic products
- Various combination and glaucoma-related ophthalmic medicines
Akten was one of the company’s better-known branded specialty products. Unlike a conventional generic, Akten was marketed as a branded ophthalmic gel and was used in ophthalmic procedures. Its commercial value depended on physician familiarity, distribution, product quality, and continued regulatory compliance.
Injectable and hospital products
Akorn also supplied sterile injectable medicines used in hospitals and institutional settings. The product group included generic anesthetics, anti-infective products, emergency medicines, and other injectable formulations.
Sterile injectables are exposed to manufacturing interruptions because a single facility problem can affect supply across multiple products. This creates commercial opportunity when supply is reliable, but it also increases regulatory and operational risk.
Acquired and legacy assets
Akorn expanded through acquisitions, including Hi-Tech Pharmacal, acquired in 2014, and VersaPharm, acquired in 2015. These transactions expanded its generic, ophthalmic, oral, and specialty product portfolios.[2]
The acquired assets increased product breadth but also created integration, manufacturing, quality-system, and regulatory obligations. For a company with limited financial scale, the cumulative compliance burden became material.
What caused Akorn’s competitive decline?
Akorn’s decline resulted from the interaction of regulatory problems, customer confidence issues, litigation, debt, and product supply disruption.
FDA manufacturing and data-integrity concerns
The FDA identified significant compliance issues at Akorn facilities. Warning letters and inspection findings addressed areas including data integrity, laboratory controls, investigations, equipment maintenance, and compliance with current good manufacturing practice requirements.[3]
These findings affected Akorn in several ways:
- They increased remediation costs.
- They delayed or threatened product approvals.
- They impaired the company’s ability to supply products consistently.
- They reduced confidence among customers and acquisition partners.
- They weakened the value of manufacturing assets.
In generic pharmaceuticals, a product approval has limited commercial value if the associated facility cannot reliably manufacture and release product.
Fresenius acquisition collapse
Fresenius Kabi agreed in 2017 to acquire Akorn for approximately $4.75 billion, including assumed debt.[4] Fresenius terminated the transaction in 2018 after citing material changes in Akorn’s business and alleged failures to comply with regulatory obligations.
The Delaware Court of Chancery ruled that Fresenius had a contractual right to terminate the transaction. The ruling was upheld on appeal.[5] The failed acquisition removed Akorn’s expected liquidity event and left the company responsible for its debt, remediation costs, and operating losses.
Financial distress and Chapter 11
Akorn filed for bankruptcy protection in 2020 and completed a restructuring. The company later filed for Chapter 11 again in February 2023.[6]
The second filing reflected:
- Declining operating performance
- Supply-chain and manufacturing disruptions
- Heavy debt obligations
- Reduced customer confidence
- Regulatory remediation costs
- Limited access to capital
- A weakened product pipeline
The 2023 proceeding was associated with a wind-down and liquidation strategy rather than a conventional recapitalization designed to restore Akorn as an independent growth company.
What was Akorn’s Orange Book and patent position?
Akorn’s patent estate was smaller and less strategically important than the patent estates of branded pharmaceutical companies. Its legal protection generally depended on product-specific patents, formulation claims, method-of-use claims, regulatory exclusivity, trademarks, trade secrets, and manufacturing know-how.
Orange Book listings
Akorn’s relevant products could have been protected through patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The commercial significance of any listing depended on:
- The specific reference-listed drug
- Patent type and expiration date
- Whether the patent was active at the time of an ANDA filing
- The scope of the claims
- Whether the product had a therapeutic-equivalence rating
- Whether a generic applicant submitted a Paragraph IV certification
The Orange Book should be reviewed at the product level. Akorn’s corporate name alone does not identify the full scope of its patent position. Patent ownership could also differ from marketing authorization ownership because of licensing, acquisition, or assignment arrangements.[7]
Formulation and delivery-system protection
The most defensible intellectual property in Akorn’s portfolio was likely concentrated in specialized dosage forms rather than basic active ingredients.
Relevant protection categories included:
- Ophthalmic gels and suspensions
- Preservative systems
- Sterile injectable compositions
- Container-closure systems
- Dosing devices
- Stability and particulate-control methods
- Manufacturing processes for sterile products
- Specific concentrations or combinations
- Method-of-use claims for ophthalmic procedures
Formulation patents can delay generic entry when they claim a commercially important property that is difficult to design around. Their strength is weaker when the claims cover routine excipients, conventional concentrations, or features that can be avoided through a straightforward alternative formulation.
Manufacturing and trade-secret barriers
Akorn’s manufacturing know-how may have had greater practical value than its publicly visible patent estate. Sterile manufacturing requires validated processes, environmental controls, analytical methods, process capability data, and regulatory history.
Those assets can create entry barriers even when patent protection is limited. They do not, however, provide the same exclusionary rights as an issued patent. Competitors can enter if they develop an alternative process and obtain FDA approval.
When did Akorn lose exclusivity and what were the generic entry risks?
Akorn’s products did not share a single exclusivity date. Exclusivity depended on whether a product was:
- A conventional generic
- A branded generic
- A 505(b)(2) product
- A product with new formulation claims
- A product with method-of-use patents
- A product protected by pediatric or orphan exclusivity
- A product subject to a licensed patent
For many generic products, the main commercial risk was not patent expiry. It was rapid price erosion after multiple ANDA approvals. A product with no meaningful patent barrier could experience substantial price compression once several competitors entered.
For ophthalmic and sterile injectable products, entry risk was more complex. The product might have limited patent protection but remain difficult to enter because of:
- FDA approval requirements
- Sterile manufacturing capacity
- Drug-shortage economics
- Device or container compatibility
- Complex analytical testing
- Limited availability of reference samples
- Facility inspection requirements
A competitor assessing an Akorn product should separate legal exclusivity from practical supply barriers. Patent expiry may permit entry, while manufacturing complexity may still constrain the number of effective competitors.
Which companies competed with Akorn?
Akorn competed against large generic manufacturers, specialty ophthalmic companies, hospital-drug suppliers, and smaller ANDA holders.
| Competitor |
Relevant competitive exposure |
| Viatris |
Broad U.S. generic portfolio, ophthalmics, injectables and institutional products |
| Teva |
Large generic scale, sterile products and specialty generics |
| Sandoz |
Global generic and biosimilar portfolio |
| Amneal |
U.S. generics, complex products and specialty pharmaceuticals |
| Fresenius Kabi |
Injectable and hospital-focused products; former acquisition counterparty |
| Hikma Pharmaceuticals |
Injectable medicines and institutional products |
| Bausch + Lomb |
Ophthalmic commercial infrastructure and branded eye-care products |
| NRx and smaller ANDA companies |
Product-specific competition in ophthalmic and injectable markets |
| Contract manufacturers |
Potential buyers or operators of manufacturing assets |
Akorn’s competitive weakness was scale. Larger companies could spread quality, regulatory, legal, and commercial costs across broader portfolios. Smaller companies could compete effectively in individual products if they had a low-cost manufacturing route or a first-to-market ANDA.
What patent litigation affected Akorn?
The most consequential litigation was not a conventional Paragraph IV patent case. It was the dispute over Fresenius’ termination of the acquisition agreement.
Fresenius-Akorn litigation timeline
| Date |
Event |
| April 2017 |
Fresenius Kabi agreed to acquire Akorn for approximately $4.75 billion |
| 2018 |
Fresenius terminated the transaction |
| October 2018 |
Delaware Court of Chancery ruled for Fresenius |
| 2019 |
Delaware Supreme Court declined to reverse the lower-court ruling |
| 2020 |
Akorn completed a bankruptcy restructuring |
| February 2023 |
Akorn filed for Chapter 11 again |
| 2023 |
The company pursued liquidation and asset dispositions |
The case is important because it connected regulatory compliance failures with transaction termination rights. The court found that the deterioration in Akorn’s business and compliance condition was sufficient to support Fresenius’ termination under the merger agreement.[5]
Publicly reported Akorn risks were therefore more heavily associated with corporate litigation, FDA compliance, bankruptcy, and supply disruption than with a large portfolio of branded-drug Paragraph IV disputes.
What was Akorn’s FDA regulatory status?
Akorn’s FDA position was impaired by inspection findings, warning letters, product recalls, and manufacturing interruptions. The company’s ability to maintain approvals depended on facility remediation and ongoing compliance with current good manufacturing practice requirements.
The FDA regulatory issues affected:
- New drug applications and supplemental applications
- ANDA approvals
- Product releases
- Manufacturing-site changes
- Customer contracts
- Product availability
- Potential acquisition value
A generic drug company can lose market share without losing an approval if it cannot maintain supply. For Akorn, regulatory problems reduced both current revenue and the value of future approvals.
Did Akorn have biosimilar risk or biosimilar opportunities?
Akorn did not have a meaningful biosimilar platform comparable to Sandoz, Teva, Amgen, Biocon Biologics, or Samsung Bioepis.
Its exposure to biosimilar competition was indirect. Biosimilar risk could affect hospital procurement, ophthalmic competition, and customer budgets, but Akorn’s principal products were small-molecule generics and specialty formulations rather than complex biologics.
Akorn also lacked the capital base, clinical infrastructure, interchangeability strategy, and manufacturing platform required to become a major U.S. biosimilar competitor.
What licensing deals and strategic transactions shaped Akorn?
The most important strategic transaction was Fresenius Kabi’s proposed acquisition. Akorn also used acquisitions to expand its portfolio and manufacturing footprint.
The key transactions were:
- Acquisition of Hi-Tech Pharmacal in 2014
- Acquisition of VersaPharm in 2015
- Proposed Fresenius Kabi acquisition in 2017
- Bankruptcy restructuring in 2020
- Second Chapter 11 filing and liquidation process in 2023
The Fresenius transaction was not completed and did not provide Akorn with the expected strategic capital. The failed deal also exposed the economic consequences of regulatory and quality-system weaknesses in a regulated pharmaceutical business.
How strong was Akorn’s patent estate?
Akorn’s patent estate was moderate at the product level but weak as a corporate-wide competitive moat.
Strengths
- Specialized ophthalmic formulations
- Sterile injectable manufacturing know-how
- Product-specific regulatory approvals
- Potential first-to-market positions
- Established customer relationships
- U.S.-based production assets
Weaknesses
- Limited novel-molecule protection
- Exposure to ANDA competition
- Product-specific rather than platform-wide patent coverage
- Regulatory findings that reduced asset value
- Lack of scale in legal and compliance operations
- Financial distress and uncertain continuity of commercialization
The strongest assets were likely products with limited competition, difficult manufacturing requirements, or differentiated delivery systems. The weakest assets were conventional generics with multiple approved competitors and minimal formulation differentiation.
What generic launch scenarios existed for Akorn products?
A competitor evaluating an Akorn product would typically consider four launch scenarios.
At-risk launch
A generic company may launch before patent litigation is resolved if it believes the patents are invalid, unenforceable, or not infringed. This creates damages and injunction risk.
Launch after patent expiry
This is the lowest legal-risk scenario but can still produce severe price erosion if multiple competitors enter simultaneously.
Settlement-based launch
A Paragraph IV dispute may end through a settlement that establishes a licensed entry date, supply arrangement, or other commercial terms. Public settlement terms may not reveal all economic provisions.
Supply-driven entry
If Akorn cannot supply the market, competitors may gain share through approved products, temporary manufacturing capacity, or new ANDAs. This scenario is particularly relevant to sterile injectables and ophthalmic products.
What revenue exposure did Akorn represent?
Akorn’s historical revenue exposure was meaningful before its regulatory and financial collapse. The company generated approximately $783 million in 2018 revenue, but the figure does not represent current recurring market opportunity.[1]
For commercial diligence, historical revenue should be discounted for:
- Product discontinuations
- Customer attrition
- Price erosion
- Loss of manufacturing capacity
- FDA remediation
- Bankruptcy-related disruption
- Competition from substitute products
- Uncertain transferability of approvals and contracts
The more relevant metric is product-level revenue that can be transferred to a solvent operator with compliant manufacturing capacity.
What is Akorn’s current strategic relevance?
Akorn is primarily an asset-recovery and competitive-entry case, not an operating-company growth story.
Potentially valuable assets include:
- ANDAs and approved drug applications
- Ophthalmic product rights
- Injectable product rights
- Manufacturing equipment
- Technical dossiers
- Customer contracts
- Trademarks such as Akten
- Process documentation and know-how
- Facility-related regulatory history
Potential buyers would need to determine whether each asset is transferable, saleable, FDA-compliant, and commercially viable. A buyer acquiring an approval without reliable manufacturing capacity may inherit regulatory liabilities without capturing sustainable revenue.
Key Takeaways
- Akorn was a specialty generic pharmaceutical company, not a biotechnology platform company.
- Its strongest commercial areas were ophthalmic drugs and sterile injectables.
- The company’s 2018 revenue was approximately $783 million, but later financial distress materially reduced the value of that base.
- FDA compliance issues and manufacturing reliability were central competitive risks.
- Fresenius Kabi’s proposed $4.75 billion acquisition failed after litigation over regulatory and business deterioration.
- Akorn filed for Chapter 11 again in February 2023 and pursued liquidation.
- Its patent estate was product-specific and less important than its regulatory approvals, manufacturing know-how, and specialized dosage forms.
- Biosimilar competition was not a core Akorn risk because the company lacked a significant biologics portfolio.
- Generic entry risks varied by product and depended on Orange Book patents, ANDA competition, sterile manufacturing barriers, and supply continuity.
- The most relevant opportunity for competitors is the acquisition or replacement of selected Akorn products, approvals, and manufacturing capabilities.
FAQs About Akorn’s Competitive Landscape
Is Akorn still an active pharmaceutical company?
Akorn entered a second Chapter 11 proceeding in 2023 and pursued liquidation and asset dispositions. Its former products and intellectual property may remain relevant through transfers, sales, or replacement suppliers.
Did Fresenius Kabi acquire Akorn?
No. Fresenius Kabi terminated the proposed acquisition, and Delaware courts upheld the termination.
Was Akorn exposed to Paragraph IV patent challenges?
Akorn products could be subject to Paragraph IV certifications where Orange Book-listed patents applied, but Akorn’s most consequential public legal dispute involved Fresenius rather than a major branded-drug patent case.
Which Akorn products had the strongest competitive barriers?
Specialized ophthalmic products and sterile injectables generally had stronger practical barriers than conventional oral generics because of formulation, manufacturing, analytical, and regulatory requirements.
Can a competitor buy Akorn’s FDA approvals?
FDA approvals and related assets may be transferred through bankruptcy or commercial transactions, but transferability, regulatory compliance, manufacturing-site status, and FDA reporting obligations must be evaluated for each product.
References
- Akorn, Inc. (2019). Annual report for the fiscal year ended December 31, 2018. U.S. Securities and Exchange Commission. https://www.sec.gov/ixviewer/doc/action?doc=
- Akorn, Inc. (2015). Annual report for the fiscal year ended December 31, 2014. U.S. Securities and Exchange Commission. https://www.sec.gov/
- U.S. Food and Drug Administration. (2018-2023). FDA warning letters and inspection-related information concerning Akorn facilities. https://www.fda.gov/
- Fresenius Kabi AG. (2017). Fresenius Kabi to acquire Akorn, Inc. https://www.fresenius-kabi.com/
- Delaware Court of Chancery. (2018). In re: Akorn, Inc. litigation. https://courts.delaware.gov/
- United States Bankruptcy Court for the District of Delaware. (2023). In re Akorn Operating Company LLC, Chapter 11 proceedings. https://www.deb.uscourts.gov/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
